熱點掃描 | 醫藥外包概念普漲，藥明康德漲超11%
uSMART盈立智投3月10日消息，截止發稿，港股三大指數齊漲，恆生指數上漲1.85%，報21011.54點，成交額572.84億；國企指數上漲1.97%，報7328.45點，成交額193.24億；紅籌指數上漲1.21%，報4002.54點，成交額24.05億。
醫藥外包概念普漲，藥明康德漲超11%，方達控股漲近7%，藥明生物、凱萊英漲超5%；
航空股集體拉昇，中國南方航空上漲7.53%，國泰航空、中國東方航空、中國國航漲超5%；
在線教育板塊走高，新東方、思考樂教育漲超6%，楓葉教育上漲4.11%，新東方在線漲超2%；
熱門股
保誠上漲5.26% ，報114港元，該集團表示，於2021年，中國內地、印度、馬來西亞、菲律賓、新加坡及泰國等主要市場均錄得可觀增長，若撇除香港，則年度保費等值銷售額增長16%。年度保費等值銷售額的增加，以及業務組合優化帶來的新業務利潤率改善，帶動集團新業務利潤上升13%；
天立教育上漲18.52%，報0.634港元，天立教育公佈，於2022年03月08日回購239.9萬股，每股回購價0.60港元，涉資143.94萬元。本年內至今爲止(自普通決議案通過以來) 累計購回證券數目爲1000萬股，佔於普通決議案通過時已發行股份數目的0.462%；
海昌海洋公園漲超11%，報3.29港元，海昌海洋公園盈喜，與2020年度淨虧損14.79億人民幣相比，預計2021年度將錄得淨利潤不少於8.3億人民幣。主要源於年內錄得出售四個主題公園的單次及非經常性收益。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.
